Together, we established mouse models that reproduced SCAR20 pathology, described the associated mechanisms underlying SCAR20 pathogenesis, and identified the use of the antiepileptic agent VPA as a potential corrective therapy for cerebellar atrophy and ataxia. This evidence concerns the gene SNX14 and Cerebellar atrophy.